Show Filters

Searches all publications.

Search Fulltext



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21



19422 items
7:50 PM, Oct 19, 2018  |  BioCentury | Product Development

New shops for value-based deals

Value-based payment models are starting to appear beyond the high-profile insurers and PBMs that have dominated the scene, with a series of deals struck since August by the Oklahoma Health Care Authority and the University...
7:10 PM, Oct 19, 2018  |  BioCentury | Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
6:04 PM, Oct 19, 2018  |  BioCentury | Politics, Policy & Law

PhRMA and Trump: war or peace?

HHS Secretary Alex Azar’s proposal to require price disclosures in television advertisements for drugs is forcing the biopharma industry to think hard about its relationship with the Trump administration. The fundamental decision is whether it...
4:30 PM, Oct 19, 2018  |  BioCentury | Finance

Earnings on deck

Earnings on deck At least 11 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q CompanyDatePre/post mkt3Q18 EPS est3Q17 EPSExpected chgBiogen Inc. (NASDAQ:BIIB)10/23Pre$6.78$6.317%Illumina Inc. (NASDAQ:ILMN)10/23Post$1.26$1.1114%Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)10/24Pre$1.74$1.4421%Anika Therapeutics Inc. (NASDAQ:ANIK)10/24Post$0.31$0.46-33%Vertex Pharmaceuticals...
4:23 PM, Oct 19, 2018  |  BioCentury | Finance

CuraSen’s SPARK

After debuting with a $54.5 million series A round, CuraSen Therapeutics Inc. hopes to generate clinical proof-of-concept data for at least two neurodegenerative disease programs in the next three years. New Leaf Venture Partners led the...
3:46 PM, Oct 19, 2018  |  BioCentury | Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
1:46 PM, Oct 19, 2018  |  BioCentury | Finance

Taiho ups its stakes

After bumping up its evergreen fund from $50 million to $300 million, Taiho Ventures LLC plans to increase its stakes in its portfolio companies. The strategic venture arm of Taiho Pharmaceutical Co. Ltd. launched in 2016...
11:41 AM, Oct 19, 2018  |  BioCentury | Finance

Warp Drive’s winding road to Revolution

After winding through nearly seven years of shifting strategies and a delayed entry into the clinic, Warp Drive Bio Inc. has opted for a takeout by fellow Third Rock Ventures portfolio company Revolution Medicines Inc....
9:17 PM, Oct 12, 2018  |  BioCentury | Product Development

Trevena goes for MOR than morphine

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee meeting on pain candidate oliceridine from Trevena Inc. gave the agency little reason to reverse its skepticism about the molecule’s benefits and risks. But it did leave...
8:01 PM, Oct 12, 2018  |  BioCentury | Politics, Policy & Law

COI failure fallout

Jose Baselga resigned as CMO of Memorial Sloan Kettering Cancer Center after being accused of failing to disclose conflicts of interest, upsetting a hornet’s nest on his way out the door that is causing academic...